This is the www.biotechnologynews.net headline for the CBIO results from their 02/08/11 article.
"Cbio receives positive trial results"
First paragraph "DRUG development company Cbio has had positive results from the Phase IIa study of its drug XToll to treat rheumatoid arthritis."
Most of it is a rehash of the announcement but the article focussed on the positives.
Additional though but not new sentiment is the statement "Cbio managing director Jason Yeates said the company was looking to commercialise the drug with global pharmaceutical companies. 'The next step is a clinical trial to determine the optimal dose of XToll with subcutaneous administration,' Yeates said."
For the full article http://www.biotechnologynews.net/storyview.asp?storyid=2420950§ionsource=s0&highlight=IO%
CBZ Price at posting:
29.2¢ Sentiment: Buy Disclosure: Held
